Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2
4(80.0%)
Phase 1
1(20.0%)
5Total
Phase 2(4)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06496607Phase 2Active Not Recruiting

A Study to Evaluate Solriktug in Adult Participants With Asthma

Role: collaborator

NCT06132256Phase 2Active Not Recruiting

MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Role: collaborator

NCT06496620Phase 2Recruiting

A Study to Evaluate Solrikitug in Participants With COPD (ZION)

Role: collaborator

NCT06329401Phase 2Recruiting

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

Role: collaborator

NCT05802264Phase 1Recruiting

Study to Assess Amphotericin B Cystetic for Inhalation (ABCI) Doses in Healthy Volunteers & People with Cystic Fibrosis

Role: collaborator

All 5 trials loaded